{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:35:31Z","timestamp":1788550531214,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100007398","name":"Strategiske Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["10-092793"],"award-info":[{"award-number":["10-092793"]}],"id":[{"id":"10.13039\/100007398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007398","name":"Strategiske Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["10-092793"],"award-info":[{"award-number":["10-092793"]}],"id":[{"id":"10.13039\/100007398","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2518-4","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T09:39:38Z","timestamp":1469007578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study"],"prefix":"10.1186","volume":"16","author":[{"given":"Sarah","family":"Preisler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matejka","family":"Rebolj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte M\u00f8ller","family":"Ejegod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsebeth","family":"Lynge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Rygaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Bonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,20]]},"reference":[{"key":"2518_CR1","unstructured":"NHS Cervical Screening Programme. HPV triage and test of cure in the cervical screening programme in England. http:\/\/www.cancerscreening.nhs.uk\/cervical\/hpv-triage-test-of-cure.html . Accessed 12 August 2015."},{"key":"2518_CR2","unstructured":"NHS Cervical Screening Programme. HPV primary screening in the NHS Cervical Screening Programme. http:\/\/www.cancerscreening.nhs.uk\/cervical\/hpv-primary-screening.html Accessed 12 August 2015."},{"issue":"2","key":"2518_CR3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","volume":"136","author":"WK Huh","year":"2015","unstructured":"Huh WK. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136(2):178\u201382.","journal-title":"Gynecol Oncol"},{"key":"2518_CR4","doi-asserted-by":"publisher","unstructured":"Ronco G, Dillner J, Elfstr\u00f6m KM, Tunesi S, Snijders PJF, Arbyn M et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. The Lancet. 2014;383(9916):524\u201332. doi:http:\/\/dx.doi.org\/ 10.1016\/S0140-6736(13)62218-7 .","DOI":"10.1016\/S0140-6736(13)62218-7"},{"issue":"4","key":"2518_CR5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","volume":"10","author":"V Bouvard","year":"2009","unstructured":"Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens--part B: biological agents. Lancet Oncol. 2009;10(4):321\u20132.","journal-title":"Lancet Oncol"},{"issue":"11","key":"2518_CR6","first-page":"1394","volume":"11","author":"PE Castle","year":"2002","unstructured":"Castle PE, Schiffman M, Burk RD, Wacholder S, Hildesheim A, Herrero R, et al. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1394\u20139.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"2518_CR7","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1128\/JCM.00824-08","volume":"46","author":"PE Castle","year":"2008","unstructured":"Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol. 2008;46(8):2595\u2013604. doi: 10.1128\/JCM.00824-08 .","journal-title":"J Clin Microbiol"},{"issue":"9","key":"2518_CR8","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1128\/jcm.01047-13","volume":"51","author":"A Gillio-Tos","year":"2013","unstructured":"Gillio-Tos A, De Marco L, Carozzi FM, Del Mistro A, Girlando S, Burroni E, et al. Clinical Impact of the Analytical Specificity of the Hybrid Capture 2 Test: Data from the New Technologies for Cervical Cancer (NTCC) Study. J Clin Microbiol. 2013;51(9):2901\u20137. doi: 10.1128\/jcm.01047-13 .","journal-title":"J Clin Microbiol"},{"issue":"Suppl 3","key":"2518_CR9","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S1386-6532(02)00187-7","volume":"25","author":"M Poljak","year":"2002","unstructured":"Poljak M, Marin IJ, Seme K, Vince A. Hybrid capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol. 2002;25 Suppl 3:S89\u201397.","journal-title":"J Clin Virol"},{"issue":"5","key":"2518_CR10","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1128\/JCM.02580-06","volume":"45","author":"M Safaeian","year":"2007","unstructured":"Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, Van Doorn LJ, et al. Comparison of the SPF10-LiPA system to the hybrid capture 2 assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in guanacaste, costa rica. J Clin Microbiol. 2007;45(5):1447\u201354. doi: 10.1128\/JCM.02580-06 .","journal-title":"J Clin Microbiol"},{"issue":"10","key":"2518_CR11","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1038\/sj.bjc.6604324","volume":"98","author":"A Sargent","year":"2008","unstructured":"Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer. 2008;98(10):1704\u20139. doi: 10.1038\/sj.bjc.6604324 .","journal-title":"Br J Cancer"},{"issue":"1","key":"2518_CR12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1186\/1471-2334-14-413","volume":"14","author":"J Bonde","year":"2014","unstructured":"Bonde J, Rebolj M, Ejegod D, Preisler S, Lynge E, Rygaard C. HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray system. BMC Infect Dis. 2014;14(1):413.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"2518_CR13","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.vaccine.2012.12.084","volume":"31","author":"B Goldman","year":"2013","unstructured":"Goldman B, Rebolj M, Rygaard C, Preisler S, Ejegod DM, Lynge E, et al. Patterns of cervical coinfection with multiple human papilloma virus types in a screening population in denmark. Vaccine. 2013;31(12):1604\u20139. doi: 10.1016\/j.vaccine.2012.12.084 .","journal-title":"Vaccine"},{"issue":"3","key":"2518_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059765","volume":"8","author":"S Preisler","year":"2013","unstructured":"Preisler S, Rebolj M, Untermann A, Ejegod DM, Lynge E, Rygaard C, et al. Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the roche cobas HPV real-time PCR assay. PLoS One. 2013;8(3), e59765. doi: 10.1371\/journal.pone.0059765 .","journal-title":"PLoS One"},{"key":"2518_CR15","doi-asserted-by":"publisher","unstructured":"Rebolj M, Lynge E, Ejegod D, Preisler S, Rygaard C, Bonde J. Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology. Gynecologic Oncology. 2014;135(3):474\u201380. doi:http:\/\/dx.doi.org\/ 10.1016\/j.ygyno.2014.10.014 .","DOI":"10.1016\/j.ygyno.2014.10.014"},{"key":"2518_CR16","doi-asserted-by":"publisher","unstructured":"Rebolj M, Preisler S, Ejegod DM, Bonde J, Rygaard C, Lynge E. Prevalence of Human Papillomavirus Infection in Unselected SurePath Samples Using the APTIMA HPV mRNA Assay. The Journal of Molecular Diagnostics. 2013;15(5):670\u20137. doi:http:\/\/dx.doi.org\/ 10.1016\/j.jmoldx.2013.04.002 .","DOI":"10.1016\/j.jmoldx.2013.04.002"},{"issue":"1","key":"2518_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086835","volume":"9","author":"M Rebolj","year":"2014","unstructured":"Rebolj M, Preisler S, Ejegod DM, Rygaard C, Lynge E, Bonde J. Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening. PLoS One. 2014;9(1), e86835. doi: 10.1371\/journal.pone.0086835 .","journal-title":"PLoS One"},{"issue":"Suppl 7","key":"2518_CR18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1403494810393563","volume":"39","author":"B Bjerregaard","year":"2011","unstructured":"Bjerregaard B, Larsen O. The danish pathology register. Scand J Public Health. 2011;39 Suppl 7:72\u20134.","journal-title":"Scand J Public Health"},{"issue":"7","key":"2518_CR19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nrclinonc.2010.96","volume":"7","author":"PE Castle","year":"2010","unstructured":"Castle PE. Screening: HPV testing for cervical cancer: the good, the bad, and the ugly. Nat Rev Clin Oncol. 2010;7(7):364\u20135.","journal-title":"Nat Rev Clin Oncol"},{"key":"2518_CR20","unstructured":"Roche. Cobas HPV test. https:\/\/www.hpv16and18.com\/labs\/medical-value\/assay-design.html . Accessed 12 August 2015."},{"key":"2518_CR21","unstructured":"Hologic. APTIMA HPV Assay Package Insert. http:\/\/www.hologic.com\/package-inserts\/clinical-diagnosticsand-blood-screening\/assays-and-tests\/aptima-hpv-assay Accessed 11 July 2016."},{"issue":"4","key":"2518_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jmoldx.2011.03.007","volume":"13","author":"M Steinau","year":"2011","unstructured":"Steinau M, Patel SS, Unger ER. Efficient DNA extraction for HPV genotyping in formalin-fixed, paraffin-embedded tissues. J Mol Diagn : JMD. 2011;13(4):377\u201381. doi: 10.1016\/j.jmoldx.2011.03.007 .","journal-title":"J Mol Diagn : JMD"},{"issue":"5","key":"2518_CR23","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/ijc.28115","volume":"133","author":"E Meites","year":"2013","unstructured":"Meites E, Lin C, Unger ER, Steinau M, Patel S, Markowitz LE, et al. Can clinical tests help monitor human papillomavirus vaccine impact? Int J Cancer. 2013;133(5):1101\u20136. doi: 10.1002\/ijc.28115 .","journal-title":"Int J Cancer"},{"key":"2518_CR24","first-page":"257","volume":"34","author":"A Chranioti","year":"2012","unstructured":"Chranioti A, Spathis A, Aga E, Meristoudis C, Pappas A, Panayiotides I, et al. Comparison of two commercially available methods for HPV genotyping: CLART HPV2 and linear array HPV genotyping tests. Anal Quant Cytol Histol. 2012;34:257\u201363.","journal-title":"Anal Quant Cytol Histol"},{"key":"2518_CR25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0463.2010.2602.x","volume":"118","author":"N Mejlhede","year":"2010","unstructured":"Mejlhede N, Pedersen B, Frisch M, Fomsgaard A. Multiple human papilloma virus types in cervical infections: competition or synergy? APMIS. 2010;118:346\u201352.","journal-title":"APMIS"},{"key":"2518_CR26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/jmv.21952","volume":"83","author":"A Pista","year":"2011","unstructured":"Pista A, Verdasca N, Oliveira A. Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test. J Med Virol. 2011;83:272\u20136.","journal-title":"J Med Virol"},{"key":"2518_CR27","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1158\/1055-9965.EPI-08-0508","volume":"17","author":"A Szarewski","year":"2008","unstructured":"Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev. 2008;17:3033\u201342.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2518_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12885-015-1223-z","volume":"15","author":"DM Ejegod","year":"2015","unstructured":"Ejegod DM, Rebolj M, Bonde J. Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to linear array and hybrid capture 2: a split-sample study. BMC Cancer. 2015;15:216. doi: 10.1186\/s12885-015-1223-z .","journal-title":"BMC Cancer"},{"issue":"2","key":"2518_CR29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1128\/jcm.02453-13","volume":"52","author":"C Eklund","year":"2014","unstructured":"Eklund C, Forslund O, Wallin K-L, Dillner J. Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet international proficiency study. J Clin Microbiol. 2014;52(2):449\u201359. doi: 10.1128\/jcm.02453-13 .","journal-title":"J Clin Microbiol"},{"issue":"20","key":"2518_CR30","doi-asserted-by":"publisher","first-page":"10112","DOI":"10.1158\/0008-5472.can-06-1812","volume":"66","author":"MB Kovacic","year":"2006","unstructured":"Kovacic MB, Castle PE, Herrero R, Schiffman M, Sherman ME, Wacholder S, et al. Relationships of human papillomavirus type, qualitative viral load, and Age with cytologic abnormality. Cancer Res. 2006;66(20):10112\u20139. doi: 10.1158\/0008-5472.can-06-1812 .","journal-title":"Cancer Res"},{"key":"2518_CR31","doi-asserted-by":"publisher","unstructured":"Lowe B, O\u2019Neil D, Loeffert D, Nazarenko I. Distribution of Human papillomavirus load in clinical specimens. Journal of Virological Methods. 2011;173(1):150\u20132. doi:http:\/\/dx.doi.org\/ 10.1016\/j.jviromet.2011.01.018 .","DOI":"10.1016\/j.jviromet.2011.01.018"},{"key":"2518_CR32","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.7314\/APJCP.2012.13.7.3281","volume":"13","author":"SUU Siriaunkgul","year":"2012","unstructured":"Siriaunkgul SUU, Suwiwat S, Settakorn J, Sukpan K, Srisomboon J, Khunamornpong S. Prognostic value of HPV18 DNA viral load in patients with early-stage neuroendocrine carcinoma of the uterine cervix. Asian Pac J Cancer Prev. 2012;13:3281\u20135.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"9","key":"2518_CR33","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1158\/1055-9965.epi-09-0482","volume":"18","author":"LF Xi","year":"2009","unstructured":"Xi LF, Edelstein ZR, Meyers C, Ho J, Cherne SL, Schiffman M. Human papillomavirus types 16 and 18 DNA load in relation to coexistence of other types, particularly those in the same species. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2507\u201312. doi: 10.1158\/1055-9965.epi-09-0482 .","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2518-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T14:49:43Z","timestamp":1498315783000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2518-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,20]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2518"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2518-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,20]]},"article-number":"510"}}